INCY News and Press, Incyte Corporation From 01/06/23

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Summary ARK Genomic Revolution ETF invests in small-cap and mid-cap companies engaged in genomic revolution, i.e., in the research of genomic sequencing, analysis, synthesis, or instrumentation. Alpha-generating stocks ARKG selects from time to time and backs for a longer time period ha...

Summary ARK Invest does great deep-dive research. Utilize their insights along with market timing considerations to generate alpha. The performance of ARKG is dictated mostly by interest rate decisions in the current environment. But underneath the macro layer, there are many promising ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, ...

Investors have experienced a difficult past 12 months in the market, and even many household names in the investing world haven't escaped the downturn. That goes for Cathie Wood, CEO of Florida-based investment firm Ark Invest. Most of Wood's actively managed funds have lagged the market this yea...

InnoCare Pharma said tafasitamab in combination with  lenalidomide, sold as Revlimid by Bristol-Myers Squibb ( BMY ), was approved in Hong Kong to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell tran...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Major indices such as the  S&P 500  and the  Nasdaq Composite  may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of...

Summary Focus still remains on advancing balstilimab, but instead of just using it alone as a monotherapy against advanced cancers, it is being moved forward together with botensilimab. The phase 2 ACTIVATE program will use botensilimab either alone or in combination with balstilimab fo...

- INCA033989, a new anti-mutant calreticulin (CALR)-targeted monoclonal antibody, represents important research milestone in myelofibrosis (MF) and essential thrombocythemia (ET) - INCA033989 abstract selected as one of only six ASH plenary presentations - ...

- Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi ® ) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF) - Initial results of a Phase 1/2 study evaluating the safety and tolerability...